Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren vs Lisinopril in Elderly Patients with Essential Hypertension
NCT00219167Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2005
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aliskiren in essential hypertension (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline in average 24 hour systolic ambulatory blood pressure at 8 weeks. Started Apr 2005; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00219167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00219167.